aripiprazole + methylphenidate

Aripiprazole + methylphenidate is a combination of two pharmaceutical agents used primarily in the management of neuropsychiatric disorders in children and adolescents, particularly when comorbid conditions are present. Aripiprazole is an atypical antipsychotic that acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, and as an antagonist at serotonin 5-HT2A receptors. Methylphenidate is a central nervous system stimulant that inhibits the reuptake of dopamine and norepinephrine, increasing their synaptic concentrations. This combination has been studied for use in patients with disruptive mood dysregulation disorder (DMDD) comorbid with attention-deficit/hyperactivity disorder (ADHD), showing improvements in irritability, externalizing symptoms, depression, anxiety, attention deficits, social problems, and cognitive function. It has also been explored for use in juvenile bipolar disorder with ADHD. The combination may have unique side effect risks such as hiccups or acute dystonia due to pharmacokinetic interactions affecting aripiprazole metabolism[1][2][4][5][7].

Other names

methylphenidate and aripiprazolearipiprazole/methylphenidate combination